Knight, T., & Callaghan, M. U. (2018). The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A. Ther Adv Hematol.
Citação norma ChicagoKnight, Tristan, and Michael U. Callaghan. "The Role of Emicizumab, a Bispecific Factor IXa- and Factor X-directed Antibody, for the Prevention of Bleeding Episodes in Patients With Hemophilia A." Ther Adv Hematol 2018.
Citação norma MLAKnight, Tristan, and Michael U. Callaghan. "The Role of Emicizumab, a Bispecific Factor IXa- and Factor X-directed Antibody, for the Prevention of Bleeding Episodes in Patients With Hemophilia A." Ther Adv Hematol 2018.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.